Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

PURPOSE: Dasatinib inhibits src family kinases and has anti-angiogenic properties. We conducted a phase I study of dasatinib, capecitabine, oxaliplatin, and bevacizumab (CapeOx/bevacizumab), with an expansion cohort in metastatic colorectal cancer (CRC). METHODS: Patients were enrolled in a dose esc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Strickler, John H., McCall, Shannon, Nixon, Andrew B., Brady, John C., Pang, Herbert, Rushing, Christel, Cohn, Allen, Starodub, Alexander, Arrowood, Christy, Haley, Sherri, Meadows, Kellen L., Morse, Michael A., Uronis, Hope E., Blobe, Gerard C., Hsu, S. David, Zafar, S. Yousuf, Hurwitz, Herbert I.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4108590/
https://ncbi.nlm.nih.gov/pubmed/24173967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0042-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados